Discover new drugs with anti-Candida activity from four unique sources: antimicrobial-producing microorganisms, plant tissue cultures, """"""""immunoliposome""""""""-encapsulated anti-Candida drugs, and novel cell wall inhibitory analogs from syntheticchemical efforts of our laboratories. In vitro models for initial rapid evaluation of potentially active drugs from thesources mentioned above will be used. These in vitro models will allow us to ascertain MIC values by established methods. Since the fungal cell wall contains enzymes and components not found in human tissue, the evaluation screens will focus on compounds that inhibit fungal cell wall synthesis to develop a drug that is pathogen-specific. Animal model evaluation of potential drugs based on in vitro tests will utilize an established mouse animal of candidiasis. Parameters of the animal model systems will be varied to determine the method and route of administration, timing and dosage necessary for anti-Candida activity, and toxicity.
